Hemab Secures $157m in Funding for Bleeding Disorder Treatments
Hemab Therapeutics has successfully completed an oversubscribed Series C funding round, raising $157m to further develop therapies for bleeding disorders.
Following the completion of a Phase II trial of sutacimig, Hemab is preparing to progress to a registration trial in 2026.
Investment Round Details
- The investment round was led by Sofinnova Partners.
- A global asset management company, a sovereign wealth fund, and Avoro Capital Advisors contributed to the round.
- New investors joined, along with continued support from existing stakeholders, including Access Biotechnology, Avoro Ventures, Deep Track Capital, Invus, Maj Invest Equity, Novo Holdings, RA Capital Management, and Rock Springs Capital.
As a result of this funding, Sofinnova partner Joe Anderson will join the Hemab board.
No direct quote available in the given text.
Author's summary: Hemab Therapeutics raises $157m for bleeding disorder treatments.
More News
- Bitmovin debuts real-time Observability suite for video playback
- Reimagining Nail Care: Turning Self-Care Into an Engine for Equity
- Billionaire Mackenzie Scott donates $101 million to UMES, Morgan State - WTOP News
- World's Tiniest Pixel Shatters Records... But There's a Catch
- Almonty Industries to acquire tungsten project in Montana, US
- Trump’s Leadership Challenges Democrats’ Distorted Narrative Effectively
- Eavor is about to bring its first-of-a-kind geothermal project online
- “No Faux King Way”: ‘No Kings’ Protesters Fighting Against Trumpism And White Christian Nationalists - Black Star News
- Elon Musk’s Unveils Grokipedia - IT News Africa | Business Technology, Telecoms and Startup News
- Popular Thai Restaurant to Open Third Sioux Falls Location Soon